Evidence map›Paper›PMID 25746563›Full record

Trial reportNeurology2015

Ictal adipokines are associated with pain severity and treatment response in episodic migraine.

Nu Cindy Chai, Bizu Gelaye, Gretchen E Tietjen, Paul D Dash, Barbara A Gower, Linda W White, Thomas N Ward, Ann I Scher, B Lee Peterlin

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Serological Biomarkers of Chronic Migraine.Current pain and headache reports · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Obesity and Migraine in Childhood.Current pain and headache reports · 2018
    Review
  12. The Serum Levels of Resistin and Its Relationship with Other Proinflammatory Cytokines in Patients with Alzheimer's Disease.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2017
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Nu Cindy ChaiFrom the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD.
Bizu GelayeFrom the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD.
Gretchen E TietjenFrom the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD.
Paul D DashFrom the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD.
Barbara A GowerFrom the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD.
Linda W WhiteFrom the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD.
Thomas N WardFrom the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD.
Ann I ScherFrom the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD.
B Lee PeterlinFrom the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD. lpeterlin@jhmi.edu.
Dartmouth–Hitchcock Medical Center · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of Toledo · US

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2000 to 2026
$31.9M
Impact and Mechansims of Migraine Comorbidites on Migraine Onset and ProgressionK23NS078345 · NINDS · JOHNS HOPKINS UNIVERSITY · PI PETERLIN, BARBARA LEE · 2012 to 2016
$888k
NIDDK NIH HHS P30 DK056336NINDS NIH HHS K23 NS078345NINDS NIH HHS K23-NS078345
6 · The paper itself

Abstract

objectiveTo evaluate ictal adipokine levels in episodic migraineurs and their association with pain severity and treatment response.

methodsThis was a double-blind, placebo-controlled trial evaluating peripheral blood specimens from episodic migraineurs at acute pain onset and 30 to 120 minutes after treatment with sumatriptan/naproxen sodium vs placebo. Total adiponectin (T-ADP), ADP multimers (high molecular weight [HMW], middle molecular weight, and low molecular weight [LMW]), leptin, and resistin levels were evaluated by immunoassays.

resultsThirty-four participants (17 responders, 17 nonresponders) were included. In all participants, pretreatment pain severity increased with every quartile increase in both the HMW:T-ADP ratio (coefficient of variation [CV] 0.51; 95% confidence interval [CI]: 0.08, 0.93; p = 0.019) and resistin levels (CV 0.58; 95% CI: 0.21, 0.96; p = 0.002), but was not associated with quartile changes in leptin levels. In responders, T-ADP (CV -0.98; 95% CI: -1.88, -0.08; p = 0.031) and resistin (CV -0.95; 95% CI: -1.83, -0.07; p = 0.034) levels decreased 120 minutes after treatment as compared with pretreatment. In addition, in responders, the HMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p = 0.041) decreased and the LMW:T-ADP ratio (CV 0.04; 95% CI: 0.01, 0.07; p = 0.043) increased at 120 minutes after treatment. In nonresponders, the LMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p = 0.018) decreased 120 minutes after treatment. Leptin was not associated with treatment response.

conclusionsBoth pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels. Adipokines represent potential novel migraine biomarkers and drug targets.

Indexed as

Migraine DisordersSeverity of Illness IndexTreatment OutcomeAdipokinesAdultCyclooxygenase InhibitorsDouble-Blind MethodDrug CombinationsFemaleHumansMaleMiddle AgedNaproxenPlacebosSumatriptanVasoconstrictor AgentsAdipokinesCyclooxygenase InhibitorsDrug CombinationsNaproxenPlacebosSumatriptanVasoconstrictor Agents

Identifiers

PMID25746563
PMCPMC4395883
OpenAlexW2003559634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.